US Stock MarketDetailed Quotes
TGTX TG Therapeutics
- 35.070
- 0.0000.00%
Close Nov 22 16:00 ET
- 35.650
- +0.580+1.65%
Pre 09:25 ET
5.46BMarket Cap-350700P/E (TTM)
0.000High0.000Low0Volume0.000Open35.070Pre Close0.00Turnover0.00%Turnover Ratio389.67P/E (Static)155.67MShares36.50052wk High28.42P/B5.11BFloat Cap12.84052wk Low--Dividend TTM145.70MShs Float149414.006Historical High--Div YieldTTM0.00%Amplitude0.956Historical Low--Avg Price1Lot Size
About TG Therapeutics Company
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
Company Profile
SymbolTGTX
Company NameTG Therapeutics
Listing DateOct 7, 2005
Founded1993
CEOMr. Michael S. Weiss
MarketNASDAQ
Employees264
Fiscal Year Ends12-31
Address3020 Carrington Mill Boulevard,Suite 475
CityMorrisville
ProvinceNorth Carolina
CountryUnited States of America
Zip Code27560
Phone1-212-554-4484
Company Executives
- Name
- Position
- Salary
- Michael S. Weiss
- Chairman of the Board, Chief Executive Officer and President
- 15.84M
- Sean A. Power
- Chief Financial Officer, Treasurer and Corporate Secretary
- 1.87M
- Sagar Lonial, M.D.
- Independent Director
- 259.70K
- Kenneth Hoberman
- Independent Director
- 264.70K
- Dr. Yann Echelard
- Independent Director
- 262.20K
- Laurence N. Charney
- Lead Independent Director
- 304.70K
- Daniel Hume
- Independent Director
- 262.20K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data